Nuoweilife Announces Completion of Tens of Millions RMB Series B1 Financing and Files IPO Prospectus

Recently,NEWISH Announces Completion of B1 Round Financing Worth Tens of Millions. This round of financing was jointly invested by Broadcom Capital, Wuxi Capital Group, and Excellence Meijia, and the funds will be mainly used to advance the clinical Phase I and II studies of core pipelines.

NEWISH is a biotech innovation company focused on gene therapy and other fields, paying attention to unmet clinical needs with a unique commercial perspective. The company continuously conducts First-in-class "China-original" nucleic acid drug research with complete independent intellectual property rights.Relying on the jointly built STARi (Super Targeted Activation of T-cell Immune Response) nucleic acid drug development platform, a new generation of therapeutic cancer vaccines is being developed. Currently, the company is primarily focused on underserved clinical areas such as cervical precancerous lesions and post-surgical recurrence of liver cancer. Several novel drugs have already entered the clinical development stage, including...Therapeutic DNA gene drug for liver cancer, NWRD06, received IND approval in May 2023; Therapeutic DNA gene drug for HPV, NWRD08, in October 2023.Received IND approval.Clinical trial results show that NWRD08 has demonstrated significant advantages in both safety and efficacy. Administered via injection into the deltoid muscle of the upper arm, the drug not only avoids the trauma and potential risks associated with traditional surgery but also achieves a reduction in lesion severity within a relatively short period, promoting the clearance of the E6E7 gene or virus.It is believed that as subsequent clinical trials continue to progress, these two therapeutic vaccine drugs will bring good news to a large number of patients with precancerous cervical lesions and hepatocellular carcinoma.

The company's R&D team is led by Academician Jiang Jiandong and authoritatively guided by former clinical review experts from the CDE of the National Medical Products Administration. The core technical leaders are Dr. Liu Defang and Dr. Qi Hailong, two "Science and Technology New Stars" talents of Beijing from Peking University. The team consists of more than 10 high-caliber postdoctoral researchers and Ph.D. talents from prestigious institutions such as Peking University, Tsinghua University, Nankai University, University of Science and Technology of China, Chinese Academy of Sciences, and Chinese Academy of Medical Sciences, who are passionate about original innovation, as well as senior industrialization professionals with deep expertise in clinical medical registration. The company has obtained over 40 invention patents in fields such as cell and gene therapy and tumor vaccines. It has published multiple SCI papers as the first or corresponding author institution and received significant special funding support from the Beijing Municipal Science & Technology Commission.

E.N.D

Previous article recommendations:(Click the article title below to open the original text)

Breakthrough in hPSC Culture Process Bottleneck! Systematic Analysis of Key Issues and Countermeasures in Cultivation (Taking iPSC as an Example)

¥93,000/bottle! The pricing of the first AAV gene drug launched in China is announced

Breakthrough in Cell Technology! Enhanced Static Process Boosts iPSCs Production to 8.1 Billion/m², More Efficient and Cost-Effective

A Gene Therapy Company in China Completes Pre-A Round Financing

Over $2.1 Billion! Keyi Pharma's Cell Therapy Drug Goes Global

An Exosome Company in China Officially Opens for Production

Delivery Efficiency Increased by 1500 Times! New Delivery Technology Greatly Enhances Targeting of RNA Drugs

Nearly 100 Million! Sales Performance of the First Mesenchymal Stem Cell Therapy in the U.S. Announced, Company's Stock Price Soars

Nearly $40 Million! A Cell Therapy Company in China Completes Series B Financing

Grand Opening! Qinhuangdao First Bio-Stem Cell Technology Company Junzhen Hospital Boosts High-Quality Development of the Life and Health Industry

Stock Price Surges Over 700%! Breakthrough Progress in a Cell Therapy Product

World's First! Bayer Subsidiary Completes First Patient Dosing in iPS Cell Therapy for Primary Photoreceptor Disease

FDA Rejects Approval of World's First Exosome Cell Therapy

6 Hours to Complete CAR-T Preparation, No Chemotherapy Lymphodepletion, 100% Remission with No Severe Side Effects: World's First Triple-Target Hematologic Tumor CAR-T Cell Drug Achieves Milestone Results

Stock Price Surges 515%, Cell Therapy Company's Core Pipeline Shows Impressive Clinical Data

Breakthrough in AAV Vector Bottleneck: Another Latest Groundbreaking Achievement in Gene Therapy Published in China

New Breakthrough in iPS Cell Technology: Production Cost Drops by Over 90%, Production Cycle Shortened to 3 Weeks